ATTR-CM

Regulatory authorities in the European Union (EU) have recommended approval of Tafamidis Accord, a generic version of Vyndaqel (tafamidis), an approved treatment for adults with hereditary…

Women with transthyretin amyloid cardiomyopathy (ATTR-CM) had worse outcomes than men in a new study, but the gap may reflect differences in age and…

A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who carry the most common TTR…

Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein and heart damage markers in…

The injectable therapy eplontersen failed to show a significant benefit over a placebo at reducing cardiovascular events and related deaths in a Phase 3…

Amvuttra (vutrisiran) rapidly and consistently reduces blood levels of transthyretin (TTR), the disease-causing protein in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), across a…

Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with the rare heart disease, potentially…

Collecting and analyzing wrist tissue for the presence of hallmark toxic protein clumps may not be sufficient as a stand-alone strategy for early detection of…

For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with significant long-term…

People carrying the p.V142I mutation in the TTR gene — which is mostly associated with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) — often have polyneuropathy,…